CGYE19140 / NRG-GY018 / Richard MooreResearch Question:
How well does the combination of pembrolizumab, paclitaxel, and carboplatin work compared
with paclitaxel and carboplatin alone in treating patients with uterine (endometrial)
cancer that is stage III, IV, or has come back (recurrent).
Basic Study Information
Purpose:Location: University of Rochester Medical Center
This phase III trial studies how well the combination of pembrolizumab, paclitaxel
and carboplatin works compared with paclitaxel and carboplatin alone in treating patients
with endometrial cancer that is stage III or IV, or has come back (recurrent). Immunotherapy
with monoclonal antibodies, such as pembrolizumab, may help the body's immune system
attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Paclitaxel and carboplatin are chemotherapy drugs used as part of the usual treatment
approach for this type of cancer. This study aims to assess if adding immunotherapy
to these drugs is better or worse than the usual approach for treatment of this cancer.
Study Reference #: CGYE19140
Lead Researcher (Principal Investigator)
Study Contact InformationStudy Coordinator: Nichole Ransom
Phone: +1 585-276-8747
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search